What Has Been the Growth of the Emerging Infectious Disease Diagnostics Market So Far?
The emerging infectious disease diagnostics market has seen considerable growth due to a variety of factors.
• The market for diagnostics of emerging infectious diseases has been experiencing robust growth in the last few years. The market is predicted to surge from $22.13 billion in 2024 to $24.34 billion in 2025, with a compound annual growth rate (CAGR) of 10.0%.
Factors contributing to the growth during the historical period may include a growing interest in point-of-care diagnostics, rising cases of infectious diseases, larger global population density, increased incidences of infectious diseases and a rise in healthcare expenditure.
How Will the Emerging Infectious Disease Diagnostics Market?
The emerging infectious disease diagnostics market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of the emerging infectious disease diagnostics is forecasted to significantly grow in the upcoming years. By 2029, it is presumed to reach $35.21 billion, with a compound annual growth rate (CAGR) of 9.7%.
Factors influencing this growth during the forecast period include increased occurrence of zoonotic diseases, substantial developments in regulatory shifts and aid, advancements in universal vaccines, and heightened emphasis on a one health approach, coupled with increased government support and funding. The period is also projected to see major trends like technology advancements, next-generation sequencing (NGS), isothermal amplification procedures, telemedicine and remote diagnostics and monitoring of environmental pathogens.
Which Factors Are Boosting Growth In The Emerging Infectious Disease Diagnostics Market?
The increasing prevalence of zoonotic diseases is predicted to stimulate growth in the emerging infectious disease diagnostics market. These diseases are infections transferrable from animals to humans and can be caused by bacteria, viruses, parasites, or fungi. The growth in zoonotic diseases can be attributed mainly to enhanced human-wildlife interactions, environmental degradation, and worldwide travel, which encourage pathogen transmission across different species. Diagnostics for emerging infectious diseases play a crucial role in managing zoonotic diseases by enabling prompt and precise detection of pathogens. This allows quick intervention, efficient treatment, and improved control of disease outbreaks, consequently minimizing transmission from animals to humans. For example, the State of West Virginia, a US-based government administration, stated in the 2022 Zoonotic Disease Report published in the MMWR Year 2022 that the reported cases of Lyme disease increased to 2,449 in February 2024, a substantial rise from 1,788 cases reported in 2021. Therefore, the growth of zoonotic diseases is fueling the drive in the emerging infectious disease diagnostics market.
What Key Areas Define The Segmentation Of The Global Emerging Infectious Disease Diagnostics Market?
The emerging infectious disease diagnostics market covered in this report is segmented –
1) By Infection Type: Viral, Bacterial, Fungal, Other Infections
2) By Disease Type: Respiratory Infections, Gastrointestinal Infections, Sexually Transmitted Infections (STIs), Other Disease Types
3) By Technology: Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), Next-Generation Sequencing (NGS), Immunodiagnostics, Other Technologies
4) By Application: Laboratory Testing, Point-of-Care Testing
5) By End-User: Hospitals And Clinics, Diagnostics Laboratories, Other End-Users
Subsegments:
1) By Viral: Respiratory Viruses, Hepatitis Viruses, HIV and Retroviruses, Arboviruses, Herpesviruses, Gastrointestinal Viruses, Emerging Viral Infections
2) By Bacterial: Tuberculosis (TB), Methicillin-Resistant Staphylococcus Aureus (MRSA), Escherichia Coli (E. coli) Infections, Streptococcus and Pneumococcus Infections, Clostridium Infections, Neisseria, Emerging Drug-Resistant Bacteria
3) By Fungal: Candidiasis, Aspergillosis, Cryptococcosis, Histoplasmosis, Coccidioidomycosis, Pneumocystis Pneumonia (PCP), Emerging Fungal Infections
4) By Other Infections: Parasitic Infections, Protozoan Infections, Prion Diseases, Helminthic Infections, Non-Pathogenic or Environmental Infections
Pre-Book The Emerging Infectious Disease Diagnostics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Emerging Infectious Disease Diagnostics Market?
Leading companies in the emerging infectious disease diagnostics market are employing cutting-edge technology, such as molecular diagnostic platforms, to gain competitive traction. These platforms utilize nucleic acid amplification methods to detect pathogens with high levels of sensitivity and specificity, thereby ensuring precise diagnoses and facilitating early detection of diseases. In May 2022 for example, the American medical equipment manufacturer Becton Dickinson and Company, introduced the BD COR MX/PX System, a fully robotic diagnostic platform with high-throughput. This system enhances lab productivity by automating the entire molecular process, starting from specimen handling to results generation. Initially, its BD CTGCTV2 assay is designed to identify three common non-viral sexually transmitted infections (STIs). The BD COR MX/PX System is capable of processing up to 1,700 samples with onboard reagent and specimen capacity, operating continuously for over seven hours, and producing up to a 1,000 test results within a 24-hour period, which significantly minimizes manual intervention by laboratory personnel.
Who Are the Key Players In The Emerging Infectious Disease Diagnostics Market?
Major companies operating in the emerging infectious disease diagnostics market are:
• Roche Diagnostics
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Danaher Corporation
• Siemens Healthineers
• Becton Dickinson and Company
• Laboratory Corporation of America Holdings
• Quest Diagnostics Incorporated
• Agilent Technologies Inc.
• Hologic Inc.
• Illumina Inc.
• bioMérieux SA
• QuidelOrtho Corporation
• Bio-Rad Laboratories
• Inc.
• Qiagen N.V.
• DiaSorin S.p.A.
• Randox Laboratories Ltd.
• Meridian Bioscience Inc.
• Sekisui Diagnostics LLC
• Copan Diagnostics
• Co-Diagnostics Inc.
• T2 Biosystems Inc.
What Is The Most Dominant Region In The Emerging Infectious Disease Diagnostics Market?
North America was the largest region in the emerging infectious disease diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the emerging infectious disease diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
